STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE

QR Code

STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE

Because of the high risk of brain metastases from HER2-positive breast cancer, the study of the anticancer activity of drugs used to treat brain tumors, in particular lomustine, is of great importance. In the FVB/N Her-2 transgenic mice bearing HER2-positive breast cancer (BC HER2+), a single oral a...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. N. Stukov, S. F. Vershinina, N. A. Koziavin, T. Yu. Semiglazova, L. V. Filatova, D. Kh. Latipova, A. O. Ivantsov, V. G. Bespalov, A. L. Semenov, O. A. Belyaeva, G. S. Kireeva, V. A. Alexandrov, G. V. Tochilnikov, I. N. Vasilyeva, M. A. Maydin, M. L. Tyndyk, S. S. Kruglov, G. A. Yanus, V. N. Yurova
Format:	Article
Language:	Russian
Published:	Russian Academy of Sciences, Tomsk National Research Medical Center 2019-11-01
Series:	Сибирский онкологический журнал
Subjects:	her2-positive breast cancer her2 transgenic fvb/n mice lomustine intracranial tumor tumor growth index
Online Access:	https://www.siboncoj.ru/jour/article/view/1188
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Activity of 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propandyоl (chlonisol) versus lomustine in intracranial transplanted tumor model in mice
by: Yu. G. Zmitrichenko, et al.
Published: (2022-12-01)

Immunomorphological specifcity of HER2-low breast cancer
by: I. V. Mikhailov, et al.
Published: (2024-11-01)

A novel bispecific aptamer targeting LAG3 and HER2 enhances T cell-mediated immunotherapy against HER2-positive cancer cells
by: Rui Guo, et al.
Published: (2025-07-01)

The аntitumor effect of 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol (chlonisol) on the growth of spontaneous mammary tumors in HER-2/neu transgenic mice
by: V. A. Alexandrov, et al.
Published: (2023-06-01)

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

Clinical and morphological aspects of neoadjuvant chemotherapy efficacy in patients with aggressive luminal HER2-negative breast cancer
by: D. A. Morozov, et al.
Published: (2022-01-01)

CLINICAL CHARACTERISTICS OF BREAST CANCER WITH STEROID RECEPTORS EXPRESSION AND HER2 AMPLIFICATION
by: F. V. Moiseenko, et al.
Published: (2017-02-01)

A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer
by: A. V. Avgustinovich, et al.
Published: (2024-03-01)

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors
by: Fatemah S. Albalawi, et al.
Published: (2025-07-01)

EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER
by: O. I. Kit, et al.
Published: (2021-05-01)

Cáncer de mama HER2-bajo: una nueva era en terapias dirigidas
by: Benjamín Walbaum, MD, et al.
Published: (2025-05-01)

Assessing functional suitability of a lyophilized formulation containing designed ankyrin repeat proteins for radionuclide imaging of HER2/neu overexpression in malignant tumors
by: R. N. Varvashenya, et al.
Published: (2024-10-01)

Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer
by: Abbey Zidel, et al.
Published: (2025-05-01)

Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma
by: Niusha Momeni, et al.
Published: (2025-07-01)

Magnetically sensitive nanocomposites and magnetic liquids based on magnetite, gemcitabine, and antibody HER2
by: A. L. Petranovska, et al.
Published: (2019-11-01)

Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
by: Mark Hensley, et al.
Published: (2025-07-01)

Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
by: R. A. Murashko, et al.
Published: (2025-03-01)

HER-2-positive metastatic breast cancer: new possibilities for therapy
by: E. V. Artamonova, et al.
Published: (2014-07-01)

Effect and mechanism of HER2 antibody-drug conjugate combined with anti-PD-1 antibody in mouse bladder cancer models
by: HE Shuo, et al.
Published: (2025-07-01)

HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN GASTRIC CANCER (GC) (RESULTS OF THE MULTICENTER CLINICAL TRIAL)
by: H. C. Chung, et al.
Published: (2017-02-01)

Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases
by: G. A. Dashyan, et al.
Published: (2016-06-01)

HER2 Reactivity Pattern and Association with Various Tumor Factors in Breast Cancer Patients
by: Greeshma Ann George, et al.
Published: (2025-04-01)

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
by: A. F. Nasretdinov, et al.
Published: (2021-06-01)

STUDI IN SILICO KOMPLEKS LIGAND-RESEPTOR EUGENOL DAUN BASIL (Ocimum basilicum L.) DENGAN RESEPTOR HER2 PADA NON-SMALL CELL LUNG CANCER (NSCLC) DENGAN KONTROL GEFITINIB
by: Martina Kurnia Rohmah
Published: (2017-09-01)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)

HER2-low Breast Cancer: Salivary Metabolic Features and Therapeutic Perspectives
by: Lyudmila V. Bel’skaya
Published: (2025-06-01)

Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy
by: I. V. Kolyadina, et al.
Published: (2021-01-01)

HER2-positive breast cancer with invasive micropapillary carcinoma component shows immunosuppressive microenvironment and resistance to neoadjuvant therapy
by: Lulu Zhang, et al.
Published: (2025-08-01)

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma
by: Michael Kim, et al.
Published: (2025-08-01)

Polyethyleneimine-polyethylene glycol copolymer targeted by anti-HER2 nanobody for specific delivery of transcriptionally targeted tBid containing construct
by: Batoul Saqafi, et al.
Published: (2019-12-01)

Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
by: O. D. Bragina, et al.
Published: (2022-10-01)

Silver Jubilee of HER2 targeting: a clinical success in breast cancer
by: Jianli Zhao, et al.
Published: (2025-08-01)

NEW INDICATORS OF HSP27 FUNCTIONAL STATE IN BREAST CANCER CELLS WITH DIFFERENT VARIANTS OF HER2/NEU-STATUS
by: E. V. Kaigorodova, et al.
Published: (2016-02-01)

<sup>89</sup>Zr-Radiolabelling of p-NCS-Bz-DFO-Anti-HER2 Affibody Immunoconjugate: Characterization and Assessment of In Vitro Potential in HER2-Positive Breast Cancer Imaging
by: Maria-Roxana Tudoroiu-Cornoiu, et al.
Published: (2025-06-01)

NGS coverage accurately predicts MET and HER2 (ERBB2) gene amplifications in a real-world non-small cell lung cancer cohort
by: Adam Kowalewski, et al.
Published: (2025-07-01)

INTRATUMORAL AMPLIFICATION HETEROGENEITY IN HER2/neu-POSITIVE BREAST CANCER MOLECULAR-GENETIC SUBTYPES
by: L. N. Vashchenko, et al.
Published: (2019-11-01)

Long-term survival after multidisciplinary treatments for HER2-positive advanced gastric cancer with multiple liver and lung metastases
by: Satoshi Yoshioka, et al.
Published: (2023-08-01)

The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow’s oncologists
by: L. G. Zhukova, et al.
Published: (2020-06-01)